Polyquaternium 42

289.28

288.1735190

DTXSID8034829

Light amber/pale yellow colored clear liquid

1.103-1.1417 g/cu cm

111 °C

Completely soluble in water

10.8 mm Hg at 20 °C; 14.4 mm Hg at 25 °C

Mildly unpleasant fishy odor

Polymer

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.|Do not discharge effluent containing this product into lakes, streams, ponds, estuaries, oceans, or other waters unless in accordance with the requirements of a National Pollution Discharge Elimination System (NPDES) permit and the permitting authority has been notified in writing prior to discharge. ... For guidance contact your State Water Board or Regional Office of the EPA.

USEPA/Office of Pesticide Programs; Reregistration Eligibility Decision Document - Busan 77, EPA 739-R-07-011 (December 2007). The RED summarizes the risk assessment conclusions and outlines any risk reduction measures necessary for the pesticide to continue to be registered in the U.S.[Available from, as of July 13, 2010: http://www.epa.gov/pesticides/reregistration/status.htm]

|Warning|H400 (91.13%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]|P273, P391, and P501|Aggregated GHS information provided by 485 companies from 4 notifications to the ECHA C&L Inventory.

Personal Protective Equipment (PPE) is required for end-use products that result in classification of category I, II, or III for skin irritation. (long-sleeve shirt, long pants, shoes, socks, chemical-resistant gloves, and a chemical-resistant apron).|Personal Protective Equipment (PPE) is required for end-use products that result in classification of category I or III for eye irritation. (Chemical-resistant eyewear )

The most common symptoms reported for cases of dermal exposure were skin irritation/burning, rash, itching, and skin discoloration/redness. The most common symptoms reported for cases of inhalation exposure were minor respiratory irritation/burning. In some case, headache is reported after inhalation exposure. The symptoms associated ocular exposure including blurred vision, edema, and irritation around eyes.

LD50 Rat male oral 1952 mg/kg (95% Confidence Interval 1727 - 2203 mg/kg)|LD50 Rat female oral 2587 mg/kg (95% Confidence Interval 2059 - 3250 mg/kg)|LD50 Rabbit dermal > 2000 mg/kg|LC50 Rabbit inhl 4.0 mg/L (95% Confidence Interval 2.3 - 7.1 mg/L)

NIOSH (NOES Survey 1981-1983) has statistically estimated that 2319 workers (114 of these were female) were potentially exposed to polixetonium chloride in the US(1).Occupational exposure to polixetonium chloride may occur through inhalation and dermal contact with this compound at workplaces where polixetonium chloride is produced or used. Use data indicate that the general population may be exposed to polixetonium chloride via inhalation dermal contact with consumer products containing this compound(SRC).

(14)C-labeled Busan 77 (Purity 60%), at concentrations of 10 or 1000 mg/kg, was administered orally or intravenously to 5 CD rats/sex/dose. Expired CO2 was not detected. In the intravenous dose group, the major routes of excretion of radioactivity were via urine and feces. Over a 7 day period, approximately 52-55% of the test material administered was excreted in the urine (38-44%) and feces (11-14%); 43- 55% were found in the tissues. In a single or repeated oral dosed groups 88-106% of the test compound administered was excreted in the urine (3%) and feces (55 -105%); kidneys, liver, and spleen had a higher residue level. In these groups, tissue residue levels were low in all tissues, except kidneys. Not more than 0.14% of the administered dose was recovered in tissue. Potential for bioaccumulation at the single or repeated oral is minimal. At the highest oral dose, 85% of the administered dose was recovered in urine (14- 17%) and feces (68-71%).|(14)C-Busan 77 (purity 60%) was administered dermally to male CRL:CD BR rats (24/group) at single dose levels of 0, 2, 20, or 300 mg/rat, (0.16, 1.59 or 15.97 mg/sq cm, respectively). Less than 0.2% of the (14)C-Busan 77 was absorbed. Mean % recovery of radioactive dose ranged from 74.5 - 92.7%. Majority of the dose was recovered in the skin rinse (65.5% - 88.6%) and at the skin site (0.4% - 13.7%).

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

/SIGNS AND SYMPTOMS/ The most common symptoms reported for cases of dermal exposure were skin irritation/burning, rash, itching, and skin discoloration/redness. The most common symptoms reported for cases of inhalation exposure were minor respiratory irritation/burning. In some case, headache is reported after inhalation exposure. The symptoms associated ocular exposure including blurred vision, edema, and irritation around eyes.

MBC 115

Formulation Types: Formulation intermediate, ready to use, soluble concentrate, granular/pelleted.|Algae Clean Out W (Fritz Industries) polixetonium chloride 5.4%|Algaefix (Mars Fishcare North America) polixetonium chloride 4.5%|Algicil Algaecide (N. Jonas & Co.) polixetonium chloride60%|For more Formulations/Preparations (Complete) data for Polixetonium chloride (47 total), please visit the HSDB record page.